Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, SPD Jiangsu Pharmaceutical Co., Ltd., has received the Drug Registration Certificate (No. 2025S03530, 2025S03531) from China's National Medical Products Administration (NMPA) for the production approval of Minoxidil Tincture.

Originally developed by Johnson & Johnson, the 2% formulation of Minoxidil Tincture was first launched in the U.S. in 1988, followed by the 5% formulation in 1997. The 2% concentration is indicated for treating male pattern baldness and alopecia areata, while the 5% version is exclusively for male use in addressing the same conditions.

SPD Jiangsu submitted the registration application for this product to the NMPA in January 2024, which was subsequently accepted. As of the announcement date, the company has invested approximately RMB 6.56 million in R&D for this drug.